Serum apolipoprotein E levels predict residual cardiovascular risk in patients with chronic coronary syndrome undergoing first percutaneous coronary intervention and on-statin treatment

Little is known about the long-term impact of apolipoprotein E (apoE) on residual cardiovascular risk in patients with chronic coronary syndrome (CCS) receiving statin treatment. A total of 1109 consecutive patients (mean age, 67 ± 10 years; 83% men) with CCS who underwent their first intervention b...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2021-09, Vol.333, p.9-15
Main Authors: Fukase, Tatsuya, Dohi, Tomotaka, Chikata, Yuichi, Takahashi, Norihito, Endo, Hirohisa, Doi, Shinichiro, Nishiyama, Hiroki, Kato, Yoshiteru, Okai, Iwao, Iwata, Hiroshi, Okazaki, Shinya, Isoda, Kikuo, Miyauchi, Katsumi, Daida, Hiroyuki, Minamino, Tohru
Format: Article
Language:English
Subjects:
Apolipoprotein E
Chronic coronary syndrome
Major adverse cardiovascular events
Percutaneous coronary intervention
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the long-term impact of apolipoprotein E (apoE) on residual cardiovascular risk in patients with chronic coronary syndrome (CCS) receiving statin treatment. A total of 1109 consecutive patients (mean age, 67 ± 10 years; 83% men) with CCS who underwent their first intervention between 2000 and 2016 were included in this study. All patients had achieved low-density lipoprotein cholesterol (LDL-C)
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2021.08.021